Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pneumococcal Disease
Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
October 8th, 2008
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia -- the leading cause of bacterial pneumonia in adults. In Europe and the United States, pneumococcal pneumonia is the most common community-acquired bacterial pneumonia, for which the adult mortality rate averages between 10 to 20 percent. That rate may exceed 50 percent in high-risk groups worldwide. The results from this trial are not intended or required for inclusion in Wyeth's...
Source: Vaccine Weekly (2008-10-08)
|
